Three months after disclosing that its latest treatment for Alzheimer’s disease failed in clinical trials, Biogen (BIIB) isn’t ready to share the details with the public.
The company was widely expected to present data on the drug, called aducanumab, at next month’s Alzheimer’s Association International Conference in Los Angeles. But on Wednesday, Biogen said it was still analyzing the results from the nearly 3,000 patients in the aducanumab trials. In a statement, the company said it still planned to present the results at a later date.
About the Author Reprints
